SCHEMBL4777940

SCHEMBL4777940

Cc1[c]ccc(NC(C)C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.33
▸ MAPK14 Q16539 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HCAR3 P49019 1/20 0.33
▸ FLT3 P36888 1/20 0.32
▸ NR4A2 P43354 1/20 0.32
▸ KCNH3 Q9ULD8 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ TDP1 Q9NUW8 2/20 0.31
▸ NPSR1 Q6W5P4 2/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ HRH4 Q9H3N8 3/20 0.31
▸ GABRA1 P14867 1/20 0.31
▸ GABRG2 P18507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12541310 0.69 TDP1 (0.44) TRPM8MEN1KMT2AHCAR3FLT3
SCHEMBL14270726 0.67 FDPS (0.58) MEN1KMT2AALDH1A1GAANPSR1
SCHEMBL25150667 0.67 NOS3 (0.41) TRPM8PDE10AMAPK14MEN1KMT2A
SCHEMBL324327 0.66 — —
SCHEMBL22509681 0.65 CYP1A2 (0.52) TRPM8PDE10AMEN1KMT2AKCNH3
SCHEMBL742490 0.65 HCAR3 (0.41) TRPM8PDE10AMAPK14MEN1KMT2A
SCHEMBL15357779 0.65 FLT3 (0.41) TRPM8MAPK14HCAR3FLT3CYP1A2
SCHEMBL4984256 0.64 TSHR (0.30) —
SCHEMBL23013221 0.64 RAB9A (0.44) TRPM8PDE10AKMT2AHCAR3ALDH1A1
SCHEMBL23023572 0.64 PDE10A (0.39) TRPM8PDE10AMAPK14MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 — — EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 — — US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 — — WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 — — EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 — — US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A TRPM8 3910/4885PDE10A 3/4885MAPK14 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback